Cure8 research brief
The study suggests a microbiome–metabolite–receptor pathway (indole metabolites activating AhR) that reduces abdominal pain in a mouse model of post-colitis, which could inform future approaches to treat chronic pain in IBD patients in remission.
Researchers (microbiome, nociception, IBD), clinicians interested in IBD-related pain, and adult patients following research on pain in remission.
The study used a mouse post-colitis model to test whether AhR ligands (natural/synthetic indoles) change pain sensitivity. Oral IPyA and other AhR agonists reduced visceral hypersensitivity in male and female mice, while AhR blockers prevented those effects.
The authors link the effect to increased Kir2.2 channel transcription in TRPV1+ nociceptors and reduced dorsal-horn neuronal activity. The paper also reports metagenomic differences in indole-producing gut bacteria between sexes and disease states.
The work is preclinical (mouse) and posted as a biorxiv preprint; it is not clinical evidence that the approach is effective or safe in people. Microbiome findings are associative and sex differences were noted but require further study. Translation from mouse nociception models to human abdominal pain is uncertain.
Posted as a biorxiv preprint (not peer reviewed). Findings are from mouse experiments and metagenomic associations; clinical relevance requires further validation.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: award PJT 197940; Crohn's and Colitis Canada, award Crohn's and Colitis Canada/Pfizer Canada Women in IBD award; Department of Medicine, University of Calgary; TRIANGLE Canada
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Many people with Crohn’s disease continue to have symptoms even when inflammation is absent. This study suggests the gut microbiome — specifically sulfur-producing bacteria and hydrogen sulfide production — might explain...
This mid‑stage trial reports strong week‑44 clinical remission and endoscopic response rates for duvakitug, an investigational anti‑TL1A therapy, in both UC and Crohn’s disease — a development that could expand future...
Children with Crohn’s disease have fewer FDA‑approved advanced treatment options than adults, so clinicians and families often must choose among off‑label therapies with limited pediatric evidence.
